Eli Lilly and Company Stock price

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse 02:30:02 24/02/2024 am IST 5-day change 1st Jan Change
769.5 USD -0.01% Intraday chart for Eli Lilly and Company -1.60% +32.01%
Sales 2024 * 41.33B 3,424B Sales 2025 * 50.55B 4,188B Capitalization 693B 57,384B
Net income 2024 * 10.96B 908B Net income 2025 * 15.35B 1,272B EV / Sales 2024 * 17.1 x
Net Debt 2024 * 13.17B 1,091B Net Debt 2025 * 7.86B 651B EV / Sales 2025 * 13.9 x
P/E ratio 2024 *
63.6 x
P/E ratio 2025 *
44.8 x
Employees 43,000
Yield 2024 *
0.67%
Yield 2025 *
0.79%
Free-Float 99.71%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.01%
1 week-1.60%
Current month+19.20%
1 month+21.44%
3 months+28.02%
6 months+40.43%
Current year+32.01%
More quotes
1 week
733.24
Extreme 733.24
793.38
1 month
630.50
Extreme 630.5
794.47
Current year
579.05
Extreme 579.05
794.47
1 year
309.20
Extreme 309.2
794.47
3 years
178.58
Extreme 178.5779
794.47
5 years
101.36
Extreme 101.36
794.47
10 years
56.81
Extreme 56.81
794.47
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 01/96/01
Director of Finance/CFO 51 01/13/01
President - -
Members of the board TitleAgeSince
Director/Board Member 64 25/21/25
Director/Board Member 67 01/09/01
Director/Board Member 64 01/05/01
More insiders
Date Price Change Volume
23/24/23 769.5 -0.01% 2,394,805
22/24/22 769.6 +3.18% 3,167,403
21/24/21 745.9 -1.29% 3,548,650
20/24/20 755.7 -3.38% 4,701,094
16/24/16 782.1 +3.20% 5,009,368

Delayed Quote Nyse, February 24, 2024 at 02:30 am IST

More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (46.6%): products for treating osteoporosis, diabetes, and growth problems; - oncology (20.3%); - immunology diseases (11.8%); - neurology (6.7%): primarily drugs used in treating depression and schizophrenia; - other (14.6%). Net sales are distributed geographically as follows: the United States (59.4%), Europe (16.9%), Japan (8.3%), China (5.9%) and other (9.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
769.5 USD
Average target price
746.7 USD
Spread / Average Target
-2.96%
Consensus
1st Jan change Capi.
+32.01% 693 B $
+21.62% 550 B $
+3.25% 390 B $
+18.74% 328 B $
+14.92% 315 B $
+7.97% 213 B $
-4.95% 212 B $
-3.58% 201 B $
-3.58% 157 B $
+0.42% 155 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Eli Lilly and Company - Nyse
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer